Gladstone Institute of Cardiovascular Disease

Colorful abstract representation of cardiovascular cells, highlighting cellular structures and interactions.

Cardiovascular disease remains the world’s leading cause of death, with heart failure alone afflicting over 26 million people around the globe, and congenital malformations being the most common human birth defect. Despite decades of work, patients and doctors still need scientific and medical breakthroughs to combat these devastating diseases.

Isha Jain standing at a lab bench talking to another scientist in a lab coat
Isha Jain’s lab is interested in how the human body senses and responds to variations in oxygen levels.
Bruce Conklin standing at a lab bench, talking to another scientist who is sitting down
Bruce Conklin’s team aims to cure genetic diseases using state-of-the-art genome-engineering technology.
A team of scientists, including Deepak Srivastava (left), Arun Padmanabhan (center), and Michael Alexanian (right), uncovered how immune cells trigger a chain of events that cause fibrosis in the heart. Their findings could lead to the development of immune therapies targeting heart disease and chronic conditions in other organs.
A team of scientists, including Deepak Srivastava (left), Arun Padmanabhan (center), and Michael Alexanian (right), uncovered how immune cells trigger a chain of events that cause fibrosis in the heart. Their findings could lead to the development of immune therapies targeting heart disease and chronic conditions in other organs.
Benoit Bruneau’s lab is broadly interested in understanding how genes are turned on and off during human development, and how this process is controlled during the formation of the heart in the embryo.
Benoit Bruneau’s lab is broadly interested in understanding how genes are turned on and off during human development, and how this process is controlled during the formation of the heart in the embryo.

To address this critical situation, the Gladstone Institute of Cardiovascular Disease leverages important genetic, developmental, chemical, biological systems, computational, and engineering approaches to study heart disease and stem cell biology.

Recently, much of their work leverages two paradigm-shifting discoveries: induced pluripotent stem cells and CRISPR-Cas9 gene editing. The scientists who discovered these technologies, Shinya Yamanaka and Jennifer Doudna respectively, operate labs at Gladstone. Other Gladstone researchers have also uncovered new and more efficient ways to use these approaches to study cardiovascular disease and transform their findings into therapies that help repair damaged hearts.

Diseases & Technologies

Major Scientific Achievements

Christina Theodoris working with a scientist while sitting down at a computer going through papers

Revealed Gene Networks that Control Heart Formation

Gladstone scientists mapped gene networks that direct the development of fetal hearts, unraveling how nature tells a cell to become a heart cell and form an organ. Finding these molecules has profoundly changed our understanding of congenital heart defects, and led to the discovery of the genetic causes of heart disease, paving the way toward preventing these conditions in the future.
Scientist holding up a dish, studying it, while sitting at a lab bench

Reprogrammed Cells to Regenerate Damaged Hearts

When a heart attack occurs, blood flow is lost to a portion of the heart muscle. As a result, the heart muscle dies and cardiac fibroblasts—which make up about 50 percent of the heart—move in to form non-beating scar tissue. Gladstone investigators reprogrammed fibroblasts in a mouse heart into beating heart muscle. So, instead of forming scar tissue, the fibroblasts became beating cardiomyocytes, incorporated themselves into the heart tissue, and improved pumping of the heart. The approach of harnessing resident cells to regenerate the heart is now being developed toward clinical application within a spin-out company, Tenaya Therapeutics.

Improved Cellular Reprogramming Techniques

Improved Cellular Reprogramming Techniques

The initial discovery that adult cells can be reprogrammed into stem cells by Gladstone Investigator Shinya Yamanaka revolutionized biology, energized research into regenerative medicine, and was recognized with the 2012 Nobel Prize. Gladstone scientists identified small molecules that can replace the genetic material that was traditionally used to reprogram cells, and successfully reprogrammed fibroblasts to pluripotent stem cells using CRISPR-Cas9 technology. They also identified discrete combinations of small molecules that can reprogram fibroblasts directly into heart, neural, liver, and pancreatic cells, simplifying the process of reprogramming to specific cell types.
Two scientists standing, working with some lab equipment

Discovered Genetic Causes and Underlying Mechanisms of Heart Disease

Since 1979, Gladstone investigators have been at the forefront of heart disease research. Early on, they made significant contributions to our understanding of how cholesterol and apolipoproteins are involved in coronary artery disease. More recently, they shifted their focus to better understand early heart development and birth defects that affect the heart. They discovered genetic causes of human cardiac septal defects and valve disease, and showed how combinations of subtle genetic variation can cause human disease.
Described the Link Between Cholesterol and Heart Disease

Described the Link Between Cholesterol and Heart Disease

Gladstone scientists identified and described the characteristics of apolipoprotein E (apoE) and discovered its involvement in cholesterol metabolism and heart disease. This influential research also laid the basis for showing apoE4’s involvement in Alzheimer’s and other neurological diseases.

Our Investigators

Michael Alexanian, PhD

Michael Alexanian, PhD

Assistant Investigator, Gladstone Institutes

Benoit Bruneau, PhD

Benoit Bruneau, PhD

Director, Gladstone Institute of Cardiovascular Disease

Bruce Conklin, MD

Bruce Conklin, MD

Senior Investigator, Gladstone Institutes

Isha Jain, PhD

Isha Jain, PhD

Associate Investigator, Gladstone Institutes

Robert Mahley, MD, PhD

Robert Mahley, MD, PhD

President Emeritus and Senior Investigator

Seth Shipman, PhD

Seth Shipman, PhD

Associate Investigator, Gladstone Institutes

Deepak Srivastava, MD

Deepak Srivastava, MD

President, Gladstone Institutes

Catherine Tcheandjieu, DVM, PhD

Catherine Tcheandjieu, DVM, PhD

Assistant Investigator, Gladstone Institutes

Christina Theodoris, MD, PhD

Christina Theodoris, MD, PhD

Assistant Investigator, Gladstone Institutes

Kiichiro Tomoda, PhD

Kiichiro Tomoda, PhD

Research Investigator, Gladstone Institutes

Shinya Yamanaka, MD, PhD

Shinya Yamanaka, MD, PhD

Senior Investigator, Gladstone Institutes

Lana Zholudeva, PhD

Lana Zholudeva, PhD

Research Investigator, Gladstone Institutes

Related Centers

A researcher in a blue lab coat and teal gloves examines a small clear sample vial held up to the light in a laboratory setting.

Gladstone-CIRM Shared Resources Laboratory

Gladstone-CIRM Shared Resources Laboratory is a centralized facility at Gladstone Institutes offering a streamlined platform for stem cell-based disease modeling, drug screening, and CRISPR screening for therapeutic development.
Learn more →
iPS Cell Research Center

iPS Cell Research Center

The goal of the center is to create disruptive, borderless innovation through advanced research on induced pluripotent stem (iPS) cells.
Learn more →
A researcher in a blue lab coat and teal gloves writes calculations on the glass panel of a biosafety cabinet in a laboratory settin

Roddenberry Stem Cell Center

The Roddenberry Stem Cell Center is an international powerhouse in stem cell research.
Learn More →
Training Tomorrow's Researchers

Training Tomorrow’s Researchers

Gladstone scientists don’t just study cardiovascular disease—they teach others how to fight it too. Learn about our award-winning training programs shaping the next wave of researchers.

Explore Our Award-Winning Training Program

Director's Message

Benoit Bruneau, PhD

Director, Gladstone Institute of Cardiovascular Disease

We bring together MDs and PhDs, tissue engineers, stem cell biologists, genome engineers, and physiologists—all working toward the same goal of better understanding how the heart forms and what can go wrong in this vital organ, so that we can help people with cardiovascular disease.

We are pushing our science into areas of untapped potential.

We believe in the power of interdisciplinary research as a way to achieve something greater together than any of us could on our own. By using the newest technologies, we are pushing our science into areas of untapped potential, which will propel cardiovascular research in new and exciting directions.

FROM THE DIRECTOR

We are pushing our science into areas of untapped potential.

Photo of Benoit Bruneau, PhD

Benoit Bruneau, PhD

Director, Gladstone Institute of Cardiovascular Disease

Read the Director’s Message

Get Involved

Join the Team

Our people are our most important asset. We offer a wide array of career opportunities both in our administrative offices and in our labs.

Open Positions
Partner With Us

Discoveries don’t stay in our labs. Gladstone facilitates spinout companies to advance promising therapies, shortening the path between scientific discovery and helping real patients.

Learn More
Give

Your gift to Gladstone will allow our researchers to pursue high-quality science, focus on disease, and train the next generation of scientific thought leaders.

Donate Now